WHAT IS THE UPDATED APPROACH TO IBD MEDICAL THERAPY IN PREGNANCY AND WHAT IS KNOWN ABOUT NEONATAL OUTCOMES IN BABIES BORN TO MOTHERS WITH IBD?

Abstract

The choice of therapy for patients with inflammatory bowel disease (IBD) before, during, and after pregnancy should be based on known medication safety, individual patient disease characteristics, and risk for relapse. Active IBD itself is one of the strongest predictors of poor pregnancy outcomes1,2; therefore, the risks associated with discontinuing medications must be weighed against any risks of the medications themselves.